nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—CYP2C8—Raloxifene—osteoporosis	0.146	0.298	CbGbCtD
Tazarotene—CYP2C8—Ethinyl Estradiol—osteoporosis	0.141	0.287	CbGbCtD
Tazarotene—CYP2C8—Cholecalciferol—osteoporosis	0.113	0.23	CbGbCtD
Tazarotene—CYP2C8—Estradiol—osteoporosis	0.0908	0.185	CbGbCtD
Tazarotene—RXRB—Vitamin D Metabolism—CYP27A1—osteoporosis	0.0199	0.0897	CbGpPWpGaD
Tazarotene—RXRB—Vitamin D Metabolism—PTH—osteoporosis	0.0164	0.0742	CbGpPWpGaD
Tazarotene—Application site rash—Estradiol—osteoporosis	0.011	0.0381	CcSEcCtD
Tazarotene—Cheilitis—Ibandronate—osteoporosis	0.0102	0.0355	CcSEcCtD
Tazarotene—Pain of skin—Estradiol—osteoporosis	0.0102	0.0353	CcSEcCtD
Tazarotene—Application site erythema—Estradiol—osteoporosis	0.0102	0.0353	CcSEcCtD
Tazarotene—Stinging—Calcium Acetate—osteoporosis	0.00987	0.0342	CcSEcCtD
Tazarotene—RXRB—Vitamin D Metabolism—VDR—osteoporosis	0.00911	0.0412	CbGpPWpGaD
Tazarotene—Localized exfoliation—Estradiol—osteoporosis	0.00892	0.0309	CcSEcCtD
Tazarotene—Application site irritation—Estradiol—osteoporosis	0.00865	0.03	CcSEcCtD
Tazarotene—Blister—Estropipate—osteoporosis	0.0063	0.0218	CcSEcCtD
Tazarotene—Blister—Calcitriol—osteoporosis	0.00591	0.0205	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00494	0.0223	CbGpPWpGaD
Tazarotene—Inflammation—Estropipate—osteoporosis	0.00468	0.0162	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—ESR2—osteoporosis	0.00459	0.0207	CbGpPWpGaD
Tazarotene—Inflammation—Ibandronate—osteoporosis	0.00449	0.0156	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00443	0.02	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.0044	0.0199	CbGpPWpGaD
Tazarotene—Acne—Ethinyl Estradiol—osteoporosis	0.00437	0.0152	CcSEcCtD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00424	0.0192	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00424	0.0192	CbGpPWpGaD
Tazarotene—Blister—Conjugated Estrogens—osteoporosis	0.00416	0.0144	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—ESR2—osteoporosis	0.00412	0.0186	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00398	0.018	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.00395	0.0178	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—ESR2—osteoporosis	0.00395	0.0178	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—ESR2—osteoporosis	0.00395	0.0178	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.00378	0.0171	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.00378	0.0171	CbGpPWpGaD
Tazarotene—Inflammation—Risedronate—osteoporosis	0.0037	0.0128	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—VDR—osteoporosis	0.00364	0.0165	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00363	0.0164	CbGpPWpGaD
Tazarotene—Swelling—Ibandronate—osteoporosis	0.00358	0.0124	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00357	0.0161	CbGpPWpGaD
Tazarotene—Inflammation—Pamidronate—osteoporosis	0.00352	0.0122	CcSEcCtD
Tazarotene—Dermatitis bullous—Estropipate—osteoporosis	0.00345	0.012	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00342	0.0155	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors—VDR—osteoporosis	0.00327	0.0148	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00325	0.0147	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Calcitriol—osteoporosis	0.00324	0.0112	CcSEcCtD
Tazarotene—Inflammation—Zoledronate—osteoporosis	0.00321	0.0111	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptors—VDR—osteoporosis	0.00313	0.0142	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—VDR—osteoporosis	0.00313	0.0142	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00312	0.0141	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00312	0.0141	CbGpPWpGaD
Tazarotene—Inflammation—Conjugated Estrogens—osteoporosis	0.00309	0.0107	CcSEcCtD
Tazarotene—Dry skin—Alendronate—osteoporosis	0.00298	0.0103	CcSEcCtD
Tazarotene—Eczema—Ethinyl Estradiol—osteoporosis	0.00297	0.0103	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00288	0.013	CbGpPWpGaD
Tazarotene—Acne—Estradiol—osteoporosis	0.00285	0.0099	CcSEcCtD
Tazarotene—Oedema—Calcium Acetate—osteoporosis	0.00285	0.00989	CcSEcCtD
Tazarotene—Swelling—Pamidronate—osteoporosis	0.00281	0.00973	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—ESR1—osteoporosis	0.00278	0.0126	CbGpPWpGaD
Tazarotene—Skin discolouration—Estradiol—osteoporosis	0.00266	0.00922	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00258	0.0117	CbGpPWpGaD
Tazarotene—Swelling—Zoledronate—osteoporosis	0.00256	0.00889	CcSEcCtD
Tazarotene—Photosensitivity reaction—Alendronate—osteoporosis	0.00256	0.00888	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—ESR1—osteoporosis	0.0025	0.0113	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00248	0.0112	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00248	0.0112	CbGpPWpGaD
Tazarotene—Inflammation—Estradiol—osteoporosis	0.00248	0.00858	CcSEcCtD
Tazarotene—Swelling—Conjugated Estrogens—osteoporosis	0.00247	0.00856	CcSEcCtD
Tazarotene—Pain—Calcium Acetate—osteoporosis	0.00244	0.00846	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors—ESR1—osteoporosis	0.00239	0.0108	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—ESR1—osteoporosis	0.00239	0.0108	CbGpPWpGaD
Tazarotene—Dermatitis contact—Estradiol—osteoporosis	0.00237	0.00823	CcSEcCtD
Tazarotene—Erythema—Etidronic acid—osteoporosis	0.00229	0.00796	CcSEcCtD
Tazarotene—Skin exfoliation—Estradiol—osteoporosis	0.00229	0.00795	CcSEcCtD
Tazarotene—Dermatitis bullous—Conjugated Estrogens—osteoporosis	0.00228	0.0079	CcSEcCtD
Tazarotene—Haemoglobin—Alendronate—osteoporosis	0.00226	0.00783	CcSEcCtD
Tazarotene—Oedema peripheral—Estropipate—osteoporosis	0.00225	0.00779	CcSEcCtD
Tazarotene—Haemorrhage—Alendronate—osteoporosis	0.00225	0.00779	CcSEcCtD
Tazarotene—Oedema peripheral—Alendronate—osteoporosis	0.00221	0.00767	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.0022	0.00994	CbGpPWpGaD
Tazarotene—Haemoglobin—Ibandronate—osteoporosis	0.0022	0.00762	CcSEcCtD
Tazarotene—Haemorrhage—Ibandronate—osteoporosis	0.00219	0.00758	CcSEcCtD
Tazarotene—Oedema peripheral—Raloxifene—osteoporosis	0.00218	0.00755	CcSEcCtD
Tazarotene—Pain—Ergocalciferol—osteoporosis	0.00215	0.00747	CcSEcCtD
Tazarotene—Oedema peripheral—Ibandronate—osteoporosis	0.00215	0.00747	CcSEcCtD
Tazarotene—Haemoglobin—Calcitriol—osteoporosis	0.00215	0.00746	CcSEcCtD
Tazarotene—Haemorrhage—Calcitriol—osteoporosis	0.00214	0.00742	CcSEcCtD
Tazarotene—Pruritus—Calcium Acetate—osteoporosis	0.00202	0.007	CcSEcCtD
Tazarotene—Erythema—Estropipate—osteoporosis	0.00198	0.00688	CcSEcCtD
Tazarotene—Swelling—Estradiol—osteoporosis	0.00198	0.00685	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00197	0.00891	CbGpPWpGaD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.00196	0.00884	CbGpPWpGaD
Tazarotene—Erythema—Alendronate—osteoporosis	0.00195	0.00678	CcSEcCtD
Tazarotene—Eczema—Estradiol—osteoporosis	0.00194	0.00673	CcSEcCtD
Tazarotene—RARA—Adipogenesis—WNT1—osteoporosis	0.00193	0.00873	CbGpPWpGaD
Tazarotene—Discomfort—Etidronic acid—osteoporosis	0.00193	0.00669	CcSEcCtD
Tazarotene—Erythema—Ibandronate—osteoporosis	0.0019	0.0066	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00189	0.00855	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00189	0.00855	CbGpPWpGaD
Tazarotene—Erythema—Calcitriol—osteoporosis	0.00186	0.00646	CcSEcCtD
Tazarotene—Haemoglobin—Ethinyl Estradiol—osteoporosis	0.00186	0.00644	CcSEcCtD
Tazarotene—Haemorrhage—Ethinyl Estradiol—osteoporosis	0.00185	0.00641	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.00183	0.00825	CbGpPWpGaD
Tazarotene—Haemoglobin—Risedronate—osteoporosis	0.00181	0.00628	CcSEcCtD
Tazarotene—Haemorrhage—Risedronate—osteoporosis	0.0018	0.00625	CcSEcCtD
Tazarotene—Oedema peripheral—Risedronate—osteoporosis	0.00178	0.00616	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.00176	0.00793	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—BMP2—osteoporosis	0.00175	0.0079	CbGpPWpGaD
Tazarotene—Haemoglobin—Pamidronate—osteoporosis	0.00172	0.00597	CcSEcCtD
Tazarotene—Haemorrhage—Pamidronate—osteoporosis	0.00171	0.00594	CcSEcCtD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.00168	0.0076	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.00168	0.0076	CbGpPWpGaD
Tazarotene—Discomfort—Alendronate—osteoporosis	0.00164	0.0057	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.00164	0.0074	CbGpPWpGaD
Tazarotene—Oedema—Estropipate—osteoporosis	0.00162	0.00562	CcSEcCtD
Tazarotene—Discomfort—Ibandronate—osteoporosis	0.0016	0.00555	CcSEcCtD
Tazarotene—Dry skin—Estradiol—osteoporosis	0.0016	0.00554	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00159	0.00718	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.00157	0.0071	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.00157	0.0071	CbGpPWpGaD
Tazarotene—Discomfort—Calcitriol—osteoporosis	0.00157	0.00544	CcSEcCtD
Tazarotene—Oedema peripheral—Zoledronate—osteoporosis	0.00154	0.00535	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00152	0.00689	CbGpPWpGaD
Tazarotene—Erythema—Pamidronate—osteoporosis	0.00149	0.00517	CcSEcCtD
Tazarotene—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.00148	0.00515	CcSEcCtD
Tazarotene—Pain—Estropipate—osteoporosis	0.00139	0.0048	CcSEcCtD
Tazarotene—Photosensitivity reaction—Estradiol—osteoporosis	0.00138	0.00477	CcSEcCtD
Tazarotene—Pain—Alendronate—osteoporosis	0.00136	0.00473	CcSEcCtD
Tazarotene—Erythema—Zoledronate—osteoporosis	0.00136	0.00472	CcSEcCtD
Tazarotene—Discomfort—Ethinyl Estradiol—osteoporosis	0.00135	0.00469	CcSEcCtD
Tazarotene—Pain—Raloxifene—osteoporosis	0.00134	0.00465	CcSEcCtD
Tazarotene—Pain—Ibandronate—osteoporosis	0.00133	0.00461	CcSEcCtD
Tazarotene—Pruritus—Etidronic acid—osteoporosis	0.00132	0.00459	CcSEcCtD
Tazarotene—Oedema—Ethinyl Estradiol—osteoporosis	0.00131	0.00455	CcSEcCtD
Tazarotene—Erythema—Conjugated Estrogens—osteoporosis	0.00131	0.00455	CcSEcCtD
Tazarotene—Pain—Calcitriol—osteoporosis	0.0013	0.00451	CcSEcCtD
Tazarotene—Discomfort—Pamidronate—osteoporosis	0.00125	0.00435	CcSEcCtD
Tazarotene—Oedema—Pamidronate—osteoporosis	0.00122	0.00422	CcSEcCtD
Tazarotene—Haemoglobin—Estradiol—osteoporosis	0.00121	0.0042	CcSEcCtD
Tazarotene—Haemorrhage—Estradiol—osteoporosis	0.00121	0.00418	CcSEcCtD
Tazarotene—Oedema peripheral—Estradiol—osteoporosis	0.00119	0.00412	CcSEcCtD
Tazarotene—Rash—Etidronic acid—osteoporosis	0.00118	0.00409	CcSEcCtD
Tazarotene—Dermatitis—Etidronic acid—osteoporosis	0.00118	0.00409	CcSEcCtD
Tazarotene—Pruritus—Estropipate—osteoporosis	0.00115	0.00397	CcSEcCtD
Tazarotene—Discomfort—Zoledronate—osteoporosis	0.00115	0.00397	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00113	0.00511	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00113	0.00511	CbGpPWpGaD
Tazarotene—Pruritus—Alendronate—osteoporosis	0.00113	0.00391	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00112	0.00505	CbGpPWpGaD
Tazarotene—Oedema—Zoledronate—osteoporosis	0.00111	0.00386	CcSEcCtD
Tazarotene—Pruritus—Ibandronate—osteoporosis	0.0011	0.00381	CcSEcCtD
Tazarotene—Pain—Risedronate—osteoporosis	0.00109	0.0038	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00108	0.0049	CbGpPWpGaD
Tazarotene—Pruritus—Calcitriol—osteoporosis	0.00108	0.00373	CcSEcCtD
Tazarotene—Oedema—Conjugated Estrogens—osteoporosis	0.00107	0.00371	CcSEcCtD
Tazarotene—Erythema—Estradiol—osteoporosis	0.00105	0.00364	CcSEcCtD
Tazarotene—Pain—Pamidronate—osteoporosis	0.00104	0.00361	CcSEcCtD
Tazarotene—Rash—Estropipate—osteoporosis	0.00102	0.00354	CcSEcCtD
Tazarotene—Dermatitis—Estropipate—osteoporosis	0.00102	0.00354	CcSEcCtD
Tazarotene—Rash—Alendronate—osteoporosis	0.00101	0.00349	CcSEcCtD
Tazarotene—Dermatitis—Alendronate—osteoporosis	0.00101	0.00349	CcSEcCtD
Tazarotene—Rash—Raloxifene—osteoporosis	0.000989	0.00343	CcSEcCtD
Tazarotene—Dermatitis—Raloxifene—osteoporosis	0.000988	0.00343	CcSEcCtD
Tazarotene—Rash—Ibandronate—osteoporosis	0.000979	0.0034	CcSEcCtD
Tazarotene—Dermatitis—Ibandronate—osteoporosis	0.000979	0.00339	CcSEcCtD
Tazarotene—Rash—Calcitriol—osteoporosis	0.000959	0.00333	CcSEcCtD
Tazarotene—Dermatitis—Calcitriol—osteoporosis	0.000958	0.00332	CcSEcCtD
Tazarotene—RARA—Adipogenesis—IRS2—osteoporosis	0.000958	0.00433	CbGpPWpGaD
Tazarotene—Pain—Zoledronate—osteoporosis	0.000951	0.0033	CcSEcCtD
Tazarotene—RARA—Adipogenesis—LEP—osteoporosis	0.000937	0.00423	CbGpPWpGaD
Tazarotene—Pruritus—Ethinyl Estradiol—osteoporosis	0.000929	0.00322	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000918	0.00415	CbGpPWpGaD
Tazarotene—Pain—Conjugated Estrogens—osteoporosis	0.000915	0.00317	CcSEcCtD
Tazarotene—Pruritus—Risedronate—osteoporosis	0.000906	0.00314	CcSEcCtD
Tazarotene—Discomfort—Estradiol—osteoporosis	0.000883	0.00306	CcSEcCtD
Tazarotene—Pruritus—Pamidronate—osteoporosis	0.000861	0.00299	CcSEcCtD
Tazarotene—Oedema—Estradiol—osteoporosis	0.000857	0.00297	CcSEcCtD
Tazarotene—RARA—Adipogenesis—IRS1—osteoporosis	0.000836	0.00378	CbGpPWpGaD
Tazarotene—Rash—Ethinyl Estradiol—osteoporosis	0.000828	0.00287	CcSEcCtD
Tazarotene—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000827	0.00287	CcSEcCtD
Tazarotene—Rash—Risedronate—osteoporosis	0.000807	0.0028	CcSEcCtD
Tazarotene—Dermatitis—Risedronate—osteoporosis	0.000806	0.0028	CcSEcCtD
Tazarotene—RARG—Gene Expression—U2AF1—osteoporosis	0.000787	0.00356	CbGpPWpGaD
Tazarotene—Pruritus—Zoledronate—osteoporosis	0.000786	0.00273	CcSEcCtD
Tazarotene—RARA—Adipogenesis—IGF1—osteoporosis	0.000775	0.0035	CbGpPWpGaD
Tazarotene—Rash—Pamidronate—osteoporosis	0.000767	0.00266	CcSEcCtD
Tazarotene—Dermatitis—Pamidronate—osteoporosis	0.000767	0.00266	CcSEcCtD
Tazarotene—Pruritus—Conjugated Estrogens—osteoporosis	0.000757	0.00263	CcSEcCtD
Tazarotene—Pain—Estradiol—osteoporosis	0.000733	0.00254	CcSEcCtD
Tazarotene—RARB—Gene Expression—U2AF1—osteoporosis	0.000706	0.00319	CbGpPWpGaD
Tazarotene—Rash—Zoledronate—osteoporosis	0.000701	0.00243	CcSEcCtD
Tazarotene—Dermatitis—Zoledronate—osteoporosis	0.0007	0.00243	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000686	0.0031	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—U2AF1—osteoporosis	0.000677	0.00306	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—U2AF1—osteoporosis	0.000677	0.00306	CbGpPWpGaD
Tazarotene—Rash—Conjugated Estrogens—osteoporosis	0.000675	0.00234	CcSEcCtD
Tazarotene—Dermatitis—Conjugated Estrogens—osteoporosis	0.000674	0.00234	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000658	0.00297	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—ESR2—osteoporosis	0.000627	0.00283	CbGpPWpGaD
Tazarotene—Pruritus—Estradiol—osteoporosis	0.000606	0.0021	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000595	0.00269	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000594	0.00268	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000587	0.00265	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—RPL24—osteoporosis	0.000585	0.00264	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000569	0.00257	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—ESR2—osteoporosis	0.000562	0.00254	CbGpPWpGaD
Tazarotene—CYP2C8—Arachidonic acid metabolism—GPX1—osteoporosis	0.00056	0.00253	CbGpPWpGaD
Tazarotene—Rash—Estradiol—osteoporosis	0.00054	0.00187	CcSEcCtD
Tazarotene—Dermatitis—Estradiol—osteoporosis	0.00054	0.00187	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—ESR2—osteoporosis	0.000539	0.00243	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ESR2—osteoporosis	0.000539	0.00243	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—RPL24—osteoporosis	0.000525	0.00237	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—RPL24—osteoporosis	0.000503	0.00227	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—RPL24—osteoporosis	0.000503	0.00227	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—VDR—osteoporosis	0.000497	0.00225	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP27A1—osteoporosis	0.000487	0.0022	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000482	0.00218	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP27A1—osteoporosis	0.000481	0.00217	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TGFB1—osteoporosis	0.000464	0.0021	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—VDR—osteoporosis	0.000446	0.00202	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TNF—osteoporosis	0.000434	0.00196	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—VDR—osteoporosis	0.000428	0.00193	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—VDR—osteoporosis	0.000428	0.00193	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—ESR1—osteoporosis	0.00038	0.00172	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000357	0.00161	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000357	0.00161	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000356	0.00161	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—IL6—osteoporosis	0.00035	0.00158	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000342	0.00155	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000341	0.00154	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—ESR1—osteoporosis	0.000341	0.00154	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PSMA5—osteoporosis	0.000338	0.00153	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PSMA2—osteoporosis	0.000338	0.00153	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000332	0.0015	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ESR1—osteoporosis	0.000327	0.00148	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ESR1—osteoporosis	0.000327	0.00148	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000326	0.00147	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000319	0.00144	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000309	0.0014	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PSMA5—osteoporosis	0.000303	0.00137	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PSMA2—osteoporosis	0.000303	0.00137	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR2—osteoporosis	0.000302	0.00136	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PSMA2—osteoporosis	0.00029	0.00131	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PSMA2—osteoporosis	0.00029	0.00131	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PSMA5—osteoporosis	0.00029	0.00131	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PSMA5—osteoporosis	0.00029	0.00131	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.00029	0.00131	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR2—osteoporosis	0.000271	0.00122	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR2—osteoporosis	0.000259	0.00117	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR2—osteoporosis	0.000259	0.00117	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP19A1—osteoporosis	0.000256	0.00116	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP19A1—osteoporosis	0.000253	0.00114	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.00024	0.00109	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—VDR—osteoporosis	0.000239	0.00108	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000234	0.00106	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—VDR—osteoporosis	0.000215	0.00097	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—VDR—osteoporosis	0.000206	0.00093	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—VDR—osteoporosis	0.000206	0.00093	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—MYC—osteoporosis	0.000198	0.000893	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000187	0.000846	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ESR1—osteoporosis	0.000183	0.000827	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—MYC—osteoporosis	0.000177	0.000801	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—MYC—osteoporosis	0.00017	0.000768	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—MYC—osteoporosis	0.00017	0.000768	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ESR1—osteoporosis	0.000164	0.000741	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000159	0.000719	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ESR1—osteoporosis	0.000157	0.000711	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—ESR1—osteoporosis	0.000157	0.000711	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—POMC—osteoporosis	0.000154	0.000695	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—FDPS—osteoporosis	0.000145	0.000656	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PKM—osteoporosis	0.000145	0.000656	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GPD2—osteoporosis	0.000138	0.000622	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PGLS—osteoporosis	0.000138	0.000622	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ATIC—osteoporosis	0.000126	0.000568	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PNP—osteoporosis	0.000126	0.000568	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—OXCT1—osteoporosis	0.000107	0.000483	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CA2—osteoporosis	0.000107	0.000483	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MGLL—osteoporosis	0.000104	0.000471	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.83e-05	0.000444	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—MYC—osteoporosis	9.52e-05	0.00043	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—IDH2—osteoporosis	8.87e-05	0.000401	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—MYC—osteoporosis	8.54e-05	0.000386	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP27A1—osteoporosis	8.34e-05	0.000377	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—MYC—osteoporosis	8.18e-05	0.00037	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—MYC—osteoporosis	8.18e-05	0.00037	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ACP5—osteoporosis	8.11e-05	0.000366	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	8.01e-05	0.000362	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—TPI1—osteoporosis	7.54e-05	0.000341	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—P4HB—osteoporosis	7.09e-05	0.00032	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GAPDH—osteoporosis	6.96e-05	0.000314	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RAP1A—osteoporosis	6.78e-05	0.000306	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.91e-05	0.000267	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ENO1—osteoporosis	5.48e-05	0.000247	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PSMA2—osteoporosis	5.4e-05	0.000244	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PSMA5—osteoporosis	5.4e-05	0.000244	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP19A1—osteoporosis	4.38e-05	0.000198	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ADCY5—osteoporosis	3.58e-05	0.000162	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GPX1—osteoporosis	3.57e-05	0.000161	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—MTHFR—osteoporosis	3.29e-05	0.000149	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—POMC—osteoporosis	2.63e-05	0.000119	CbGpPWpGaD
